Golimumab is available as prefilled syringes in 50 mg and 100 mg dosage forms for subcutaneous injection and a 50 mg/4 mL (12.5 mg/mL) solution supplied in a single-dose vial for intravenous infusion. The entire volume of golimumab should be diluted with a 0.9% sodium chloride injection, USP for a cumulative volume of 100 mL. An amount equal to the whole quantity of golimumab can be withdrawn from a 100 mL infusion bag of 0.9% sodium chloride, USP, and gradually combined the total volume of golimumab solution to the 100 mL infusion bag. Any left-over solution in vials should be discarded.

**Rheumatoid Arthritis**

- 2 mg/kg is administered as an intravenous infusion at week 0, week 4, then week 8. Treatment is continued every eight weeks thereafter. The intravenous infusion is gradually administered over a 30-minute duration.

- 50 mg administered as a subcutaneous injection every four weeks.

**Psoriatic Arthritis**

- 2 mg/kg is administered as an intravenous infusion at week 0, week 4, then week 8. Treatment is continued every eight weeks thereafter. The intravenous infusion is gradually administered over a 30-minute duration.

- 50 mg administered as a subcutaneous injection every four weeks.

**Active Ankylosing Spondylitis**

- 2 mg/kg is administered as an intravenous infusion at week 0, week 4, then week 8. Treatment is continued every eight weeks thereafter. The intravenous infusion is gradually administered over a 30-minute duration.

- 50 mg administered as a subcutaneous injection every four weeks.

**Ulcerative Colitis**

- 200 mg is given as a subcutaneous injection during week 0 (initial dosage)

- 100 mg is given as a subcutaneous injection during week 2, followed by 100 mg every four weeks

**Polyarticular Juvenile Idiopathic Arthritis and Psoriatic Arthritis (pediatric patients: 2 years and older)**

- 80 mg/m^2 is administered as an intravenous infusion at week 0, week 4, then week 8. Treatment is continued every eight weeks thereafter. The intravenous infusion is gradually administered over a 30-minute duration.

Hypersensitivity reactions (angioedema, urticaria, anaphylaxis) may occur during the administration of golimumab infusion. Immediate discontinuation of golimumab and appropriate management should be initiated.